ZipBio announced an exclusive license agreement with MeiraGTx Holdings plc. Under the agreement, MeiraGTx will receive exclusive rights to ZipBio's first-in-class therapies for geographic atrophy, targeting the complement pathway, ZipBio said in a press release. 

According to the press release, the licensing deal combines MeiraGTx's leadership in vector design, clinical development, and in-house manufacturing of genetic medicines, and ZipBio's expertise in de novo-designed protein therapeutics, developed using its Compact generative artificial intelligence (AI) platform. 

Compact is ZipBio's proprietary generative AI platform for designing protein therapeutics. It enables the creation of Zip drugs—compact, multifunctional, and logic-gated proteins, the company said. 

"MeiraGTx's expertise in development of best-in-class genetic medicines in ophthalmology makes them the ideal partner to bring our next generation AI-designed Geographic Atrophy therapies to patients with a significant unmet need," said Roee Farber, MD, CEO of ZipBio, in the press release. "This license agreement allows ZipBio to concentrate on advancing our internal pipeline in immunology and cardiovascular disease, while continuing to pioneer next-generation biologics designed to target disease pathways that have historically been challenging to address. Together, this approach reflects our commitment to developing therapies that tackle some of today's most prevalent and impactful diseases."